Skip to content
DataLookout
Menu

NCT06848400

Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Mar 3, 2025 to Apr 3, 2025 Show 8 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Trial completed
    • Primary completion date changed from estimate of Dec 31, 2026 to Feb 18, 2026
    • Secondary endpoints: details revised at 11 of 13 entries
    • Study description expanded, about 8 words
    • Site details revised at 12 of 12 sites
    • Collaborators: 11 to 10
    • Publications: details revised at 6 of 8 entries
  2. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 1 to 12
    • Start date changed from estimate of Mar 1, 2025 to Mar 3, 2025
    • Study description expanded, about 269 words
    • Collaborators: 1 to 11
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Diagnostic accuracy of ACG in screening for common UGI abnormalities
Timeframe: Through study completion, an average of 1 year.

Secondary (12)

Diagnostic accuracy and average diagnostic time between AI-assisted reading and manual reading of ACG
Coverage rate of gastric anatomical sites of ACG
Inspection completion rate of ACG
Average duration of ACG
Average inspection time of ACG
Show 7 moreShow less
72-hour discharge rate of ACG
Lesion detection rate of ACG
Evaluation of image quality of ACG
Satisfaction evaluation of ACG
Evaluation of gastric cleanliness of ACG
Evaluation of gastric filling of ACG
Evaluation of degree of gastric mucosal visualization of ACG

Arms and interventions

Testing GroupExperimental

Product name: Gastric Capsule Endoscope System Specification model: GICE-1000 Manufacturer: Guangzhou Side Medical Technology Co., Ltd. Participants fast for at least 8 hours and take mucolytics and anti-foaming agents 30 minutes before the ACG. Following video instructions, they connect the capsule with mobile, activate the capsule, and swallow it with water. Participants remain blinded to real-time ACG video. Researchers observe and record whether the participants have completed the examination as instructed in the video and any adverse events (without guidance). Data will be uploaded post-exam via WiFi or the manufacturer's system. Capsule discharge will be tracked.

Control groupActive comparator

Product name: Electronic gastrointestinal endoscope (EGD) Specifications and models: GIF-290 series Manufacturer: Olympus, Tokyo, Japan EGD was the reference standard against which ACG was compared, and it was performed within 24 hours post-ACG ingestion time. Participants will fast for at least 8 hours (clear water is allowed) and take mucolytics and anti-foaming agents 30 minutes before the EGD. The EGD will then be performed by endoscopists with more than 500 EGD procedures completed, who are blinded to the ACG examination results. The procedure for this study will adhere to the Systematic Screening Protocol for the Stomach (SSS), as outlined by Yao et al(8).The endoscopists will record any lesions identified (including lesion type, location, size, number of lesions etc.), and biopsies or treatments will be performed following white-light EGD screening, if necessary. Anonymous reports, images, and videos will be exported for further analysis.

Devices: AI-integrated Capsule Gastroscopy (ACG) examination, Electronic gastroduodenoscopy (EGD) examination

Sites

12 sites in 3 countries

China 10, Hong Kong 1, Italy 1